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Background-—There remains uncertainty regarding the second-best conduit after the internal thoracic artery in coronary artery
bypass grafting. Few studies directly compared the clinical results of the radial artery (RA), right internal thoracic artery (RITA), and
saphenous vein (SV). No network meta-analysis has compared these 3 strategies.
Methods and Results-—MEDLINE and EMBASE were searched for adjusted observational studies and randomized controlled trials
comparing the RA, SV, and/or RITA as the second conduit for coronary artery bypass grafting. The primary end point was all-cause
long-term mortality. Secondary end points were operative mortality, perioperative stroke, perioperative myocardial infarction, and
deep sternal wound infection (DSWI). Pairwise and network meta-analyses were performed. A total of 149 902 patients (4
randomized, 31 observational studies) were included (RA, 16 201, SV, 112 018, RITA, 21 683). At NMA, the use of SV was
associated with higher long-term mortality compared with the RA (incidence rate ratio, 1.23; 95% CI, 1.12–1.34) and RITA
(incidence rate ratio, 1.26; 95% CI, 1.17–1.35). The risk of DSWI for SV was similar to RA but lower than RITA (odds ratio, 0.71; 95%
CI, 0.55–0.91). There were no differences for any outcome between RITA and RA, although DSWI trended higher with RITA (odds
ratio, 1.39; 95% CI, 0.92–2.1). The risk of DSWI in bilateral internal thoracic artery studies was higher when the skeletonization
technique was not used.
Conclusions-—The use of the RA or the RITA is associated with a similar and statistically significant long-term clinical benefit
compared with the SV. There are no differences in operative risk or complications between the 2 arterial conduits, but DSWI
remains a concern with bilateral ITA when skeletonization is not used. ( J Am Heart Assoc. 2019;8:e010839. DOI: 10.1161/
JAHA.118.010839.)
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O ne of the most important unresolved questions incontemporary coronary artery bypass (CABG) surgery is
the choice of the conduit to complement the internal thoracic
to left anterior descending artery anastomosis.
The radial artery (RA), the right internal thoracic artery
(RITA), and the saphenous vein (SV) are all currently being
used routinely, although the majority of the surgeons favor
the SV.
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Abundant observational evidence suggests a survival
benefit for the use of arterial grafts, and the current
guidelines encourage a wider use of the RA or the RITA,
especially in patients with a long life expectancy.1–4 However,
the reported benefit of arterial grafts has not been confirmed
in a large randomized controlled trial (RCT) , and it has been
hypothesized that the survival benefit seen in observational
studies may be due to unmatched confounders and treat-
ment allocation bias.5,6 An important additional unresolved
question is the relative role of the RITA and RA. Although
the RITA is biologically identical to the left internal thoracic
artery, data comparing the patency rate and clinical outcome
of the 2 arterial grafts has been contradictory and
inconclusive.7,8
Network meta-analysis (NMA) with adjusted indirect com-
parison among treatments is a useful technique to reduce the
potential for heterogeneity or allocation biases, in particular
when analyzing both RCTs and observational studies.9
To date, the only published NMA comparing the SV, RITA
and RA as the second conduit in CABG focused only on
angiographic patency and not on clinical outcomes.10 Due to
the well-known discrepancy between occlusion of grafts to
non–left anterior descending arteries and clinical outcomes,11
a similar analysis focusing on clinical end points is of
particular relevance to the surgical community.
Here, we performed an NMA with the aim to specifically
investigate the differences in late survival (primary outcome)
and other clinical outcomes according to the type of second
graft used for CABG.
Material and Methods
The authors declare that all supporting data are available
within the article and its online supplementary files. This
systematic review and NMA follows the Preferred Reporting
Items for Systematic Reviews and Meta-Analysis statement.12
Data Sources and Systematic Literature Review
Ovid’s version of MEDLINE and EMBASE were searched from
inception to February 2018 (full search strategy attached in
Table S1). Inclusion criteria were English language publica-
tions, adjusted or matched observational studies or RCTs
comparing RA and/or SV and/or RITA as the second conduit
for CABG. In addition, we searched recent meta-analyses and
reviews on this topic for potential additional studies. All
citations were reviewed by 3 investigators independently
(A.A., A.D.F., and M.R.), and any disagreements were resolved
by consensus. In case of overlapping studies, the largest
series were included.
Data Extraction and Quality Assessment
Data extraction was performed independently by 2 investiga-
tors (A.A. and A.D.F.). The following variables were included:
study demographics (sample size, number of centers, institu-
tions involved, publication year, study period, design and
country, length of follow-up), patient demographics (age, sex,
diabetes mellitus, and ejection fraction) and procedural (use
of skeletonization) and postoperative data. The quality of the
included studies was assessed by the Newcastle–Ottawa
Scale (Table S2).13 Only RCTs and observational studies of
high quality (Newcastle–Ottawa Scale score >6) were
included in the final analysis.
Outcomes
The primary outcome was all-cause long-term mortality. The
secondary outcomes were operative mortality, perioperative
stroke, perioperative myocardial infarction (MI), and deep
sternal wound infection (DSWI), as defined in the original
articles.
Two levels of analyses were conducted for all outcomes:
(1) pairwise meta-analysis between arterial grafts (with either
RITA or RA) and SV and between RITA and RA, and (2) network
meta-analyses between RITA, RA, and SV.
Data Synthesis and Analysis
Pairwise meta-analysis
Late outcomes were pooled as the natural logarithm of the
incident rate ratio (IRR) to account for potentially different
follow-up durations between the groups. We estimated the
IRR through several means depending on the available study
data. When hazard ratios for matched (preferentially)/ad-
justed cohorts were provided, we took the natural logarithm
Clinical Perspective
What Is New?
• The use of the radial artery or the right internal thoracic artery
is associated with a similar and statistically significant long-
term clinical benefit compared with the saphenous vein.
• There are no differences in operative risk or complications
between the two arterial conduits, but deep sternal wound
infection remains a concern with bilateral internal thoracic
artery when skeletonization is not used.
What Are the Clinical Implications?
• The results of our study support the superiority of the use of
a second arterial over venous graft, and suggest the
equivalence in long-term and perioperative outcomes
among RITA and radial artery.
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of the hazard ratio; the standard error was derived from the 95%
CI or log rank P value.14 When Kaplan–Meier curves were
present, we estimated the event rates from the curves using
GetData Graph Digitizer software 2.26 (http://getdata-graph-
digitizer.com/). In case of missing Kaplan–Meier curves, we
used the reported event rates in order to calculate the IRR, as
previously described.15,16 Short-term binary outcomes were
pooled using log odds ratio (OR) with 95% CI using the generic
inverse variance method.9 Random effect meta-analysis was
performed using meta andmetafor packages in R (version 3.3.3
R Project for Statistical Computing).17,18 Heterogeneity was
reported as low (I2=0–25%), moderate (I2=26–50%), or high
(I2 >50%).19 In random-effects meta-analysis, the extent of
variation among the effects observed in different studies
(between-study variance) is referred to as tau2 (ie, the variance
of the true effect size parameters across the population of
studies). Tau2 reflects the amount of true variance (hetero-
geneity), while tau is the estimated standard deviation of
underlying true effects across studies, and they are used to
describe the distribution of true effects; if there is no variance
between studies, tau2 is low (or zero).20–22 We reported tau2
values throughout tables and figures, as appropriate.
Sensitivity analysis using leave-one-out analysis and pub-
lication bias assessment by funnel plot and Egger’s test were
conducted for the primary outcome. Subgroup analysis was
used to compare the relative results of RITA and RA versus
SV. Meta-regression was used to explore the effect of age,
sex, diabetes mellitus, and preoperative ejection fraction on
the IRR for the primary outcome.
Network meta-analysis
Network (multiple-treatment) meta-analysis was conducted in
R (version 3.3.3 R Project for Statistical Computing) using the
“netmeta” statistical package based on the method described
by R€ucker.23–25 Inconsistency was evaluated with Cochran’s
Q.26 Pooled log IRRs with 95% CIs was used to determine the
relative effect estimates of late outcomes. ORs with 95% CIs
were used for the binary outcomes. A random-effects model
was preferentially used to improve the model fit, but results
using a fixed model were also reported.
Inconsistency in NMA was evaluated by conducting
conventional pairwise meta-analyses and testing consistency
by comparing the direct and indirect evidence. The consis-
tency equation used was lBC=lAClAB, where lAB is the
treatment effect for treatment B compared with treatment
A.27,28 We used Cochran’s Q statistic to assess inconsistency,
and the presence of P<0.05 signifies inconsistency. Statistical
significance (at the 5% level) was declared when 95% CI did
not cross the line of no effect. For the primary outcome, a
network meta-regression was used to relate the size of
treatment effect to potential effect modifiers (mean age,
percentage of female, percentage of patients with diabetes
mellitus, and mean preoperative ejection fraction). Network
meta-regression was conducted using the logit transformation
method with random-effects model with no priori. The logit
transformation was used as suggested by other authors.29,30
Results
Description of the Included Studies and of the
Population
A total of 2455 studies were retrieved and 35 met inclusion
criteria and were included in the final meta-analysis (Fig-
ure S1). Seven studies were international and multicenter; 11
studies were from the United States; 4 from Canada, 3 each
from Italy and the United Kingdom; 2 each from Japan and
Australia, and 1 each from Austria, Serbia, and Argentina
(Tables 1 and 2).31–65
A total of 149 902 patients were included (RA, 16 201; SV,
112 018; and RITA, 21 683) from 4 RCTs (n=1932) and 31
observational studies (n=147 970). Demographics of the
included studies are shown in Tables 1 and 2.
The number of patients in the individual studies ranged from
182 to 48 241 (91–4577 in the RA group, 91–46 343 in the SV
group, and 118–2215 in the RITA group). The mean age ranged
from 56.0 to 72.1 (56.3–72.1 years in the RA group, 57.1–
70.6 years in the SV group, and 56.2–69.2 in the RITA group).
Female sex ranged from 1.1 to 43.8% (1.0–43.1% in the RA
group, 1.1–41.6% in the SV group, and 7.3–43.8% in the SV
group). Most patients had a normal or low-normal ejection
fraction (range 42–59.4%). The incidence of diabetes mellitus
ranged from 5.1 to 53.2% (6.5–45.1% in the RA group, 12.0–
43.8% in the SV group, and 5.1–53.3% in the RITA group).
Pairwise Meta-Analysis
The main results of the pairwise meta-analysis are summa-
rized in Table 3.
At a mean follow-up of 6.9 years, the use of any arterial
graft (RA or RITA) was associated with lower long-term
mortality compared with the use of the SV (IRR, 0.80; 95% CI,
0.75–0.85). There was a significantly higher risk of DSWI (OR
1.27; 95% CI, 1.05–1.54) in the arterial graft group. Operative
mortality (OR, 0.68; 95% CI, 0.55–0.83), perioperative MI (OR,
0.77; 95% CI, 0.64–0.92) and perioperative stroke (OR, 0.80;
95% CI, 0.65–0.98) were lower in the arterial graft group.
The use of the RA was associated with lower long-term
mortality (IRR, 0.81; 95% CI, 0.73–0.90) at a mean follow-up
of 8.1 years compared with the SV. Operative mortality (OR,
0.66; 95% CI, 0.46–0.95) and perioperative stroke (OR, 0.73;
95% CI, 0.54–1.00) were lower in the RA group, while the risk
of perioperative MI (OR, 0.67, 95% CI, 0.42–1.07), and DSWI
were similar (OR, 1.10; 95% CI, 0.80–1.51).
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Table 1. Characteristics of the Included Studies
Author/Year Study Period Mean/Median SD Follow-Up (Years) Hospitals/Centers Type
Benedetto 201331 1996–2012 6.43.6 Papworth Hospital, Cambridge, England PSM
Benedetto 201432 2001–2013 4.03.2 Harefield Hospital, London, United Kingdom PSM
Benedetto 201733 1996–2015 10.24.5 Bristol Heart Institute, United Kingdom PSM
Buxton 199834 1985–1995 4.3 Austin and Repatriation Medical Center,
University of Melbourne, Victoria, Australia
Adjusted
Calafiore 200435 1986–1999 Overall: 7.34.8
RITA: 7.15.0
SV: 7.54.7
University Hospital, Torino, Italy and
“G D’Annunzio” University, Chieti, Italy
PSM
Carrier 200936 1995–2007 10.0 Montreal Heart Institute, Montreal, Quebec, Canada Adjusted
Cohen 200137 1994–1999 Max 3.0 Sunnybrook and Women’s College Health
Sciences Centre, Toronto, Canada
PSM
Dewar 199538 1984–1992 4.0 Vancouver Hospital and Health Sciences Centre,
University of British Columbia, Vancouver, Canada
PSM
Goldman 201139 2003–2009 Max 1.0 Multicenter RCT
Goldstone 201840 2006–2011 Median arterial: 5.3 (IQR: 3.8–6.7)
Median venous: 5.2 (IQR: 3.7–6.6)
Multicenter PSM
Grau 201541 1994–2013 Overall: 10.55.0
RITA: 10.95.0
SV: 10.15.0
Columbia University College of Physicians
and Surgeons, Ridgewood, NJ, United States
PSM
Hayward 2013 (RAPCO)42 1996–2004 6 (1.8–10.4) University of Melbourne, Victoria, Australia RCT
Ioannidis 200143 1993–1996 NR Multicenter Adjusted
Janiec 201744 2001–2015 SV: 9.3 (4.2)
RA: 10.7 (4.1)
RITA: 5.5 (5.0)
Multicenter Adjusted
Kurlansky 201045 1972–1994 Overall: 11.00.5
RITA: 12.0.7.0
SV: 11.01.0
Florida Heart Research Institute, Miami, FL, United States Adjusted
LaPar 201546 2001–2013 30.0 days VCSQI database, Virginia, United States PSM
Lin 201347 1997–2001 9.4 (5.7–11.9) Cedars-Sinai Medical Center in Los Angeles, CA PSM
Locker 201348 1993–2009 7.6 Mayo Clinic, Rochester, MN, United States Adjusted
Lytle 200449 1971–1989 RITA: 16.22.4
SV: 16.32.5
The Cleveland Clinic Foundation,
Cleveland, OH, United States
PSM
Nasso 200950 2003–2006 24.19.8 months Multicenter RCT
Navia 201651 1996–2014 Median: 5.5 (IQR: 2.6–8.8) Instituto Cardiovascular de Buenos
Aires, Buenos Aires, Argentina
PSM
Parsa 201352 1984–2009 NR Duke University Medical Center,
Durham, NC, United States
Adjusted
Petrovic 201553 2001–2003 Max 8.0 Belgrade University School of Medicine,
Belgrade, Serbia
RCT
Pusca 200854 1997–2006 NR Emory University School of Medicine,
Atlanta GA, United States
Adjusted
Rosenblum 201655 2003–2013 Median: 2.8 (1.1–4.9) Emory University School of Medicine,
Atlanta, GA, United States
PSM
Ruttman 201156 2001–2010 Overall: 57.7 (3.0–112.0) months
RITA: 32.7 (3–111.0)
RA: 67.3 (3–112.0)
Innsbruck Medical University, Austria PSM
Santarpino 201057 2003–2007 3.170.07 Magna Graecia University of Catanzaro, Italy Adjusted
Continued
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The use of the RITA was associated with lower long-term
mortality (IRR, 0.80; 95% CI, 0.73–0.86) at mean 8.5 years
follow-up compared with SV. Perioperative MI (OR, 0.79; 95%
CI, 0.65–0.96) and operative mortality (OR, 0.68; 95% CI,
0.53–0.87) were lower in the RITA arm. There was no
difference in perioperative stroke (OR, 0.85; 95% CI, 0.62–
1.16), while the risk of DSWI higher in the RITA group (OR,
1.33; 95% CI, 1.04–1.69).
When directly comparing the 2 arterial grafts, the use of RITA
was associated with similar long-term mortality (IRR, 0.96; 95%
CI, 0.83–1.11) at 7.1 years’mean follow-up compared with the
RA. The risk of perioperative MI (OR, 0.32; 95% CI, 0.03–3.13)
and perioperative stroke (OR, 0.87; 95% CI, 0.45–1.68) were
similar between the 2 arterial grafts. There was a significantly
higher risk of DSWI (OR, 2.22; 95% CI, 1.09–4.54) and operative
mortality (OR, 1.76, 95% CI, 1.21–2.55) in the RITA group.When
limiting the analysis to the studies where the skeletonization
technique was used for ITA harvesting, no difference in DSWI
between the RA and RITA groups was found (Figure S2).
A subgroup analysis for the primary outcome comparing
the results of RCT versus non-RCT studies is provided in
Figure S3.
Leave-one-out analysis was robust for the primary outcome
in the main analysis (arterial grafts versus SV (Figure S4A).
Funnel plot Egger’s test intercept for the primary outcome in
arterial versus venous comparison was 0.640.46, P=0.17
(Figure S4B).
Network Meta-Analysis
The results of the NMA are summarized in Figure and Tables
S3 and S4.
The use of the SV was associated with higher late mortality
(IRR, 1.23; 95% CI, 1.12–1.34) and operative mortality (OR,
1.71; 95% CI, 1.17–2.52) compared with the RA. The risk of
perioperative MI (OR, 1.32; 95% CI, 0.84–2.07), perioperative
stroke (OR, 1.30; 95% CI, 0.90–1.88), and DSWI (OR, 0.98;
95% CI, 0.67–1.46) was not statistically different when
compared with the RA.
The use of the SV was associated with higher late mortality
(IRR, 1.26; 95% CI, 1.17–1.35), operative mortality (OR, 1.45;
95% CI, 1.14–1.84), and perioperative MI (OR, 1.30; 95% CI,
1.06–1.61) compared with the RITA. The risk of perioperative
stroke (OR, 1.24; 95% CI, 0.93–1.64) was not statistically
different, and the risk of DSWI (OR, 0.71; 95% CI, 0.55–0.91)
was lower with the SV compared with the RITA.
The use of the RITA was associated with similar late
mortality (IRR, 0.98; 95% CI, 0.89–1.07) and perioperative MI
(OR, 1.01; 95% CI, 0.62–1.65) compared with the RA. There
was a trend toward higher risk of DSWI in the RITA group (OR,
1.39; 95% CI, 0.92–2.1), while operative mortality and stroke
were similar for the 2 arteries.
At network meta-regression, mean age, percentage of
female, percentage of patients with diabetes mellitus, and
mean preoperative ejection fraction were not found to
significantly modify the treatment effect (Figure S5).
Discussion
The balance between possible better long-term clinical and
angiographic outcomes of arterial grafts and the potential risk
of harvesting site complications and the increased technical
complexity associated with their use has been the center of a
continuous debate over the past 25 years.66 Also, the relative
Table 1. Continued
Author/Year Study Period Mean/Median SD Follow-Up (Years) Hospitals/Centers Type
Schwann 201658 1987–2011 4.7 Multicenter PSM
Stevens 200459 1985–1995 Overall: 11.03.0
RITA: 8.02.0
SV: 12.03.0
Montreal Heart Institute, Montreal, Quebec, Canada Adjusted
Tarelli 200160 1988–1990 Overall: 9.2
RITA: 9.22.8
SV: 9.12.5
Varese Hospital, Varese, Italy PSM
Tranbaugh 201061 1995–2009 7.7 (0.1–13.8) Beth Israel Medical Center, New York, NY, United States PSM
Tranbaugh 201762 1995–2012 RA: 8.84.0
RITA: 8.94.9
SV: 9.1
Multicenter Adjusted
Tsuneyoshi 201563 2000–2013 6.17.8 “Kurashiki Central Hospital, Okayama, Japan” PSM
Yoshida 201764 1997–2007 7.54.4 Fukui Cardiovascular Center, Shinbo, Fukui, Japan PSM
Zacharias 200465 1996–2002 3.71.9 Mercy St Vincent Medical Center, Toledo, OH, United States PSM
IQR indicates interquartile range; NR, not reported; PSM, propensity score matched; RA, radial artery; RAPCO, Radial Artery Patency and Clinical Outcomes randomized trial; RCT,
randomized controlled trial; RITA, right internal thoracic artery; SV, saphenous vein; VCSQI, Virginia Cardiac Services Quality Initiative.
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efficacy of the RITA and RA as the second arterial grafts
remains controversial.7
Several pairwise meta-analyses on the topic have been
published previously.1,67,68 However, pairwise meta-analyses
have known limitations in terms of heterogeneity of the
included studies and potential for treatment allocation bias.
NMAs have been proposed to overcome the limitations of the
pairwise comparison, especially when summarizing the
evidence of RCTs and observational studies.9,69 It has been
suggested that NMA can be superior to classical pairwise
analyses, especially in case of comparison of a new treatment
to a standard one.70
This is the first NMA specifically addressing the differences
in clinical outcomes according to the type of second graft
used for CABG. The only published network meta-analysis on
the subject focused only on the patency rates of conduits and
did not include clinical outcomes.10 Due to the demonstrated
absence of a consistent correlation between angiographic
failure and clinical events,11 a deeper understanding of the
clinical impact of the type of second conduit used for CABG
seems of major relevance.
The results of our study support the superiority of the use
of a second arterial over venous graft, and suggest the
equivalence in long-term and perioperative outcomes between
the RITA and RA.
The superior midterm patency rate of arterial grafts
(especially the RA) has been convincingly demonstrated in
RCTs and observational studies.50,71–74 A large amount of
observational evidence also suggests a clinical benefit in
terms of survival and event-free survival for the use of the RA
Table 3. Outcomes Summary of the Pairwise Meta-Analysis
Model Studies*
Point
Estimate† 95% CI
Overall Effect
(Z-Value, P Value)
Heterogeneity
(I2, P Value) Tau2 Interpretation
Long term mortality
RA/SV 11 0.81 0.73 to 0.90  47, 0.04 0.0110 Better in RA
RITA/SV 17 0.80 0.73 to 0.86  73, <0.01 0.0136 Better in RITA
RITA/RA 9 0.96 0.83 to 1.11  57, 0.02 0.0204 ND
ART/SV 28 0.80 0.75 to 0.85 6.93, <0.0001 66, <0.01 0.0115 Better in ART
Perioperative DSWI
RA/SV 8 1.10 0.80 to 1.51  0, 0.48 0 ND
RITA/SV 14 1.33 1.04 to 1.69  24, 0.20 0.0463 Higher in RITA
RITA/RA 6 2.22 1.09 to 4.54  40, 0.14 0.2795 Higher in RITA
ART/SV 21 1.27 1.05 to 1.54 2.41, 0.0159 14, 0.27 0.0264 Higher in ART
Perioperative mortality
RA/SV 7 0.66 0.46 to 0.95 2.27, 0.0234 29, 0.21 0.0599 Better in RA
RITA/SV 17 0.68 0.53 to 0.87 3.11, 0.0019 56, 0.1327 Better in RITA
RITA/RA 7 1.76 1.21 to 2.55 2.98, 0.0029 11.7, 0.34 0.0310 Better in RA
ART/SV 24 0.68 0.55 to 0.83 3.79, 0.0002 49.1, 0.004 0.1043 Better in ART
Perioperative stroke
RA/SV 7 0.73 0.54 to 1.00  0, 0.72 0 Better in RA
RITA/SV 11 0.85 0.62 to 1.16  36, 0.11 0.0875 ND
RITA/RA 5 0.87 0.45 to 1.68  29, 0.23 0.1653 ND
ART/SV 18 0.80 0.65 to 0.98 2.11, 0.0350 14, 0.29 0.0266 Better in arterial
Perioperative MI
RA/SV 7 0.67 0.42 to 1.07  0, 0.56 0 ND
RITA/SV 8 0.79 0.65 to 0.96  0, 0.65 0 Better in RITA
RITA/RA 2 0.32 0.03 to 3.13  61.1, 0.11 1.67 ND
ART/SV 15 0.77 0.64 to 0.92 2.82, 0.0048 0, 0.73 0 Better in ART
ART indicates all arterial grafts; DSWI, deep sternal wound infections; MI, myocardial infarction; ND, no difference; RA, radial artery; RITA, right internal thoracic artery; SV, saphenous vein.
*Articles reporting the outcomes in RA, RITA, and SV cohorts were included as 3 studies (RA/SV, RITA/SV, and RITA/RA).
†Incidence rate ratio was used for long-term mortality, while odds ratio was used for operative mortality and perioperative outcomes.
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or the RITA instead of the SV as the second graft.1,7,75,76
However, we have recently shown how unmatched con-
founders are present even in the best comparative observa-
tional studies and suggested that a treatment allocation bias
may be responsible for the better clinical outcome of patients
receiving more than 1 arterial graft.6
This type of bias is potentially present even in the present
meta-analysis, but the additional power and precision of NMA
in defining relations and interactions between treatments
from the aggregated estimates of all the available evidence
should permit a more efficient comparison among different
strategies.9
Our results are in line with those of a recent patient-level
meta-analysis on the comparison between the RA and the
SV.76 However, at first sight, our results appear to contradict
the overall neutral findings of the ART (Arterial Revascular-
ization Trial), where on the primary intention-to-treat analysis,
there was no difference in survival between single and
bilateral ITA grafts at 10 years (in press). However, 40% of
patients in the ART received a different treatment from that
initially proposed and an as-treated analysis showed a
significant survival benefit in patients receiving >1 arterial
graft, consistent with the results of the current study.
Difference in sample size and length of follow-up and the
fact that in observational studies the revascularization
strategy is based on surgical judgment and not mandated
by protocol are possible explanations for these apparent
contradictions.
A key finding of this study is the demonstration of
equivalence between the RITA and RA with respect to all the
short- and long-term clinical outcomes. Of note, in our
analysis, the relative survival benefit of the RITA and RA
compared with the SV were identical (SV versus RITA and RA,
IRR, 1.26; 95% CI, 1.17–1.35). Although there was a trend
toward higher risk of DSWI with RITA, this risk became
nonsignificant in a subgroup analysis of studies where the
skeletonization of ITA was employed. This finding is in
accordance with what was reported by previous meta-
analyses7 and by a post hoc analysis of the ART.77
The literature on the comparison between the RITA and RA
is discordant. We previously published a pairwise meta-
analysis of the propensity-matched studies comparing the 2
Figure. Full network meta-analytic estimates (expressed as incidence rate ratio [IRR] and odds ratio [OR] with 95% credible interval) for the
different outcomes using random and fixed models respectively. A, Long-term mortality (SV is associated with higher long-term mortality
compared with RA; IRR=1.23, 95%CI=1.12–1.34; s2=0.0127; I2=64%); B, Operative mortality (SV is associated with higher operative mortality
compared with RA expressed as OR, 1.71; 95% CI. 1.17–2.52; s2=0.1219; I2=48.7%); C, Perioperative MI (SV is associated with similar
perioperative MI compared with RA expressed as OR=1.32, 95%CI=0.84–2.07; s2=0.0041; I2=2.1%); D, Perioperative stroke (SV is associated
with similar perioperative stroke compared with RA expressed as OR=1.30, 95%CI=0.90–1.88; s2=0.0573; I2=22%); E, Perioperative DSWI (SV is
associated with similar perioperative DSWI compared with RA expressed as OR=0.98, 95%CI=0.67–1.46; s2=0.0671; I2=25.4%I). DSWI indicates
deep sternal wound infections; MI, myocardial infarction; RA, radial artery; RITA, right internal thoracic artery; SV, saphenous vein.
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arterial grafts and found that the use of the RITA was
associated with a 25% relative reduction in the risk of long-
term mortality.7 The reason underlying the discrepancy
between our previous meta-analysis and the present findings
is probably related to the different sample size (149 902
patients with 6.9 years of follow-up for the present analysis
versus 15 374 patients and a range of 45–168 months of
follow-up for the previous pairwise comparison). Also, our
previous analysis did not include 2 recent large studies
comparing the 2 arterial grafts.33,78 Finally, the use of NMA
and direct/indirect comparisons allow for better precision
around estimates compared with pairwise comparisons.
Of note, in a large study the Society of Thoracic Surgeons
National Database of >1.4 million patients, Schwann et al8
showed significantly higher perioperative mortality and risk of
DSWI using the RITA, but not the RA, versus the SV as the
second graft—findings that were also demonstrated in the
present study. The authors also described a significant
volume-to-outcome relation for the use of the RITA but not
of the RA. Similarly, in a meta-analysis of 34 bilateral internal
thoracic artery (BITA) series and 27 000 BITA patients, we
recently identified a highly significant BITA use-to-outcome
relationship for long-term survival and incidence of DSWI that
was independent from the well-known CABG volume/out-
come effect.78 These findings suggest that BITA grafting may
be more technically demanding than the use of the single
internal thoracic artery and that a volume/outcome relation
can explain the marginally increased operative risk in the RITA
arm.
A key point when using the RA for CABG is the degree of
target vessel stenosis. It has been shown that the patency
rate of RA grafts is strongly influenced by the degree of target
coronary stenosis.79–81 In fact, a target vessel stenosis >70%
was a common criterion for using the RA in the studies
included in this meta-analysis (Table 2).
This study shares the usual limitations of meta-analyses of
observational studies.82 Despite statistical adjustment and
the use of NMA, between-studies heterogeneity remains a
source of bias. Important details such as the etiology of
follow-up of death, the protocols used to reduce the risk of
DSWI (with the exception of skeletonization of the ITA), and
the incidence of repeat revascularization were not systemat-
ically retrievable and could not be included in our analyses.
Additionally, we recognize that despite including only
adjusted studies, the presence of unmeasured confounders
and treatment allocation biases cannot be excluded.6 How-
ever, the NMA approach utilized and the low-moderate-grade
heterogeneity found across the studies should have attenu-
ated these biases.
In conclusion, in an NMA of adjusted observational and
randomized studies comparing the RA, the RITA, and the SV
as the second conduit for CABG, we found that the use of the
RITA or the RA was associated with a similar long-term clinical
benefit compared with the use of the SV. No differences in
late and operative mortality and postoperative complications
was found between the 2 arterial conduits, although DSWI
remains a concern after BITA grafting if skeletonization is not
used.
Disclosures
None.
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Table S1. Search strategy. 
Ovid MEDLINE® (Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE® Daily and Ovid MEDLINE® - 
1946 to Present); Searched on 02/22/2018 
Line # |   Search term    
1          Coronary Artery Bypass/      
2          (aorta adj2 bypass).tw.         
3          CABG.tw.          
4          (aortic coronary bypass or aorticocoronary anastomosis).tw.      
5          (aorto coronary adj2 (bypass or graft)).tw.            
6          (aortocoronary adj2 (anastomosis or bypass or shunt or graft)).tw.      
7          (coronary adj2 (bypass or graft)).tw.          
8          (Total arterial revascularization or total arterial revascularisation or Multiple arterial revascularization or multiple arterial 
revascularisation).tw.            
9          or/1-8              
10       Radial Artery/            
11       (radial arter* or arteria radialis or radialis artery).tw.      
12       10 or 11          
13       Saphenous Vein/      
14       (Saphenous Vein* or SVG or saphena vein or saphenous venos system or vena saphena).tw.            
15       13 or 14          
16       Internal Mammary-Coronary Artery Anastomosis/           
17       (Right Internal Mammary Artery or RIMA or Coronary Internal Mammary Artery or arteria mammaria interna or arteria thoracica 
interna or internal thoracic artery or mammary internal artery).tw.                  
18       (cardiac muscle revascularisation or cardiac muscle revascularization or coronary revascularisation or coronary revascularization or 
heart muscle revascularisation or heart myocardium revascularisation or heart revascularisation or heart revascularization or internal 
mammary arterial anastomosis or internal mammary arterial implantation or internal mammary artery anastomosis or internal mammary 
artery graft or internal mammary artery implant or internal mammary artery implantation or internal mammary-coronary artery 
anastomosis or myocardial revascularisation or myocardial revascularization or myocardium revascularisation or myocardium 
revascularization or transmyocardial laser revascularisation or transmyocardial laser revascularization or vineberg operation).tw.          
19       16 or 17 or 18            
20       9 and (12 or 15 or 19)         
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21       ((second or 2nd) adj3 (conduit* or graft*)).tw.     
22       (multi-vessel* or multivessel* or multiple vessel* or multi-vein* or multiple vein* or multi-arter* or multiple arter*).tw.  
23       21 or 22          
24       20 and 23       
25       limit 24 to English language 
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Table S2. Newcastle-Ottawa scale for the included studies. 
Author / Year Selection Comparability Outcome/Exposure Total 
Benedetto 20131 **** ** *** ********* 
Benedetto 20142 **** ** *** ********* 
Benedetto 20173 **** ** *** ********* 
Buxton 19984 **** ** ** ******** 
Calafiore 20045 **** ** *** ********* 
Carrier 20096 **** ** *** ********* 
Cohen 20017 **** ** * ******* 
Dewar 19958 **** ** ** ******** 
Goldman 20119 **** ** * ******* 
Goldstone 201710 **** ** *** ********* 
Grau 201511 **** ** *** ********* 
Hayward 2013 
(RAPCO)12 
**** ** *** ********* 
Ioannidis 200113 **** ** * ******* 
Janiec 201714 **** ** *** ********* 
Kurlansky 201015 **** ** *** ********* 
LaPar 201516 **** ** * ******* 
Lin 201317 **** ** *** ********* 
Locker 201318 **** * *** ******** 
Lytle 200419 **** ** *** ********* 
Nasso 200920 **** ** * ******* 
Navia 201621 **** ** *** ********* 
Parsa 201322 **** ** *** ******** 
Petrovic 201523 **** ** *** ******** 
Pusca 200824 **** ** *** ********* 
Rosenblum 201625 **** ** *** ******** 
Ruttman 201126 **** ** ** ******** 
Santarpino 201027 **** ** *** ******** 
Schwann 201628 **** ** *** ********* 
Stevens 200429 **** ** *** ******** 
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Tarelli 200130 **** ** *** ******** 
Tranbaugh 201031 **** ** *** ********* 
Tranbaugh 201732 **** ** *** ********* 
Tsuneyoshi 201533 **** ** *** ********* 
Yoshida 201734 **** ** *** ********* 
Zacharias 200435 **** ** ** ******** 
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Table S3. Comparison of direct and indirect estimates to assess inconsistency within network loops for the outcomes.  
Long term mortality Fixed effect model:  
 
 comparison  k prop   nma direct indir.  Diff     z p-value 
   RA:RITA   9 0.47  0.00  -0.01   0.02 -0.03 -0.57  0.5712 
      RA:SV 11 0.62 -0.18  -0.17  -0.19  0.03  0.57  0.5712 
   RITA :SV 17 0.91 -0.18  -0.18  -0.16 -0.03 -0.57  0.5712 
 
Random effects model:  
 
 comparison  k prop   nma direct indir.  Diff     z p-value 
   RA:RITA   9 0.53  0.02   0.03   0.02  0.01  0.11  0.9113 
      RA:SV 11 0.65 -0.21  -0.21  -0.20 -0.01 -0.11  0.9113 
   RITA :SV 17 0.82 -0.23  -0.23  -0.24  0.01  0.11  0.9113 
 
Perioperative mortality Fixed effect model:  
 
 comparison  k prop   nma direct indir.  Diff     z  p-value 
   RA:RITA   7 0.67 -0.21  -0.61   0.61 -1.22 -4.23 < 0.0001 
      RA:SV  7 0.91 -0.61  -0.51  -1.73  1.22  2.78   0.0054 
   RITA :SV 17 0.98 -0.40  -0.41  -0.11 -0.30 -0.50   0.6182 
 
Random effects model:  
 
 comparison  k prop   nma direct indir.  Diff     z p-value 
   RA:RITA   7 0.72 -0.17  -0.50   0.68 -1.18 -2.59  0.0095 
      RA:SV  7 0.82 -0.54  -0.36  -1.34  0.97  1.90  0.0575 
   RITA :SV 17 0.97 -0.37  -0.39   0.51 -0.90 -1.16  0.2459 
Perioperative MI Fixed effect model:  
 
 comparison k prop   nma direct indir.  Diff     z p-value 
   RA:RITA  2 0.11 -0.02   1.12  -0.17  1.29  1.66  0.0963 
      RA:SV 7 0.90 -0.28  -0.40   0.88 -1.29 -1.66  0.0963 
   RITA :SV 8 0.98 -0.26  -0.24  -1.52  1.29  1.66  0.0963 
 
Random effects model:  
 
 comparison k prop   nma direct indir.  Diff     z p-value 
   RA:RITA  2 0.12 -0.01   1.12  -0.16  1.28  1.65  0.0990 
      RA:SV 7 0.90 -0.28  -0.40   0.88 -1.28 -1.65  0.0990 
   RITA :SV 8 0.98 -0.27  -0.24  -1.52  1.28  1.65  0.0990 
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 Perioperative Stroke Fixed effect model:  
 
 comparison  k prop   nma direct indir.  Diff     z p-value 
   RA:RITA   5 0.59 -0.05  -0.01  -0.09  0.08  0.22  0.8248 
      RA:SV  7 0.91 -0.24  -0.31   0.45 -0.75 -1.44  0.1489 
   SV:RITA  11 0.96  0.20   0.17   0.78 -0.61 -1.15  0.2519 
 
Random effects model:  
 
 comparison  k prop   nma direct indir.  Diff     z p-value 
   RA:RITA   5 0.59 -0.05   0.06  -0.20  0.26  0.60  0.5485 
      RA:SV  7 0.87 -0.26  -0.34   0.26 -0.60 -1.09  0.2775 
   SV:RITA  11 0.94  0.21   0.17   0.95 -0.78 -1.25  0.2117 
 
Perioperative DSWI Fixed effect model:  
 
 comparison  k prop   nma direct indir.  Diff     z p-value 
   RA:RITA   6 0.63 -0.29  -0.54   0.15 -0.69 -2.00  0.0455 
      RA:SV  8 0.86  0.00   0.09  -0.54  0.63  1.49  0.1373 
   SV:RITA  14 0.95 -0.29  -0.26  -0.79  0.54  1.28  0.2001 
 
Random effects model:  
 
 comparison  k prop   nma direct indir.  Diff     z p-value 
   RA:RITA   6 0.62 -0.33  -0.63   0.15 -0.77 -1.80  0.0726 
      RA:SV  8 0.79  0.02   0.18  -0.60  0.78  1.59  0.1124 
   SV:RITA  14 0.94 -0.35  -0.29  -1.19  0.89  1.65  0.0987 
 k          - Number of studies providing direct evidence 
 prop       - Direct evidence proportion 
 nma        - Estimated treatment effect (logIRR or log OR) in network meta-analysis 
 direct     - Estimated treatment effect (logIRR or log OR) derived from direct evidence 
 indir.     - Estimated treatment effect (logIRR or log OR) derived from indirect evidence 
 Diff       - Difference between direct and indirect treatment estimates 
 z          - z-value of test for disagreement (direct versus indirect) 
 p-value    - p-value of test for disagreement (direct versus indirect) 
 
RA, radial artery; RITA, right internal artery; SV, saphenous vein.  
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Table S4. Rank scores with probability rank of different graft groups with the greatest reduction in outcomes within the different treatment groups 
(RITA, RA and SV) where the closer to one equates to the probability the therapy leads to the greatest reduction.  
 
Long term mortality       P-score (fixed) P-score (random) 
RITA           0.7875           0.8466 
RA             0.7125           0.6534 
SV             0.0000           0.0000 
Perioperative mortality       P-score (fixed) P-score (random) 
RA             0.9699           0.8967 
RITA           0.5301           0.6012 
SV             0.0000           0.0021 
Perioperative MI       P-score (fixed) P-score (random) 
RITA           0.7293           0.7361 
RA             0.7143           0.7052 
SV             0.0564           0.0587 
Perioperative stroke       P-score (fixed) P-score (random) 
RA             0.7746           0.7532 
RITA           0.6797           0.6704 
SV             0.0457           0.0764 
Perioperative DSWI       P-score (fixed) P-score (random) 
SV             0.7522           0.7638 
RA             0.7254           0.7056 
RITA           0.0224           0.0306 
 
 
 
RA, radial artery; RITA, right internal artery; SV, saphenous vein. 
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Figure S1. PRISMA flow chart of study selection.  
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Figure S2. A: Forest plot showing subgroup differences for skeletonization on deep sternal wound infection (DSWI) in RITA vs RA/SVG pairwise 
comparisons (Subgroup difference P-value=0.1933); B: Forest plot showing subgroup differences for skeletonization on deep sternal wound 
infection (DSWI) in RITA vs SVG pairwise comparisons (Subgroup difference P-value=0.4194); C: Forest plot showing subgroup differences for 
skeletonization on deep sternal wound infection (DSWI) in RITA vs RA pairwise comparisons (Subgroup difference P-value=0.2786). RA, radial artery; 
RITA, right internal artery; SV, saphenous vein. 
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Figure S3. Long-term mortality for arterial grafts (RA/RITA) vs SV in RCT vs non-RCT trials (Subgroup difference P value=0.4897).  
ART; All arterial grafts, RA; radial artery, RITA; right internal thoracic artery, SV; saphenous vein. 
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Figure S4. Leave one out (A) and Funnel plot (B) for the primary analysis. RA, radial artery; RITA, right internal artery; SV, saphenous vein. 
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Figure S5. Network meta-regression for long term mortality. A: Mean age; B: Female percent; C: Diabetes mellitus percent; D: Ejection fraction (EF) 
percent. 
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